Price Change(%) Volume

Press Release

MyoKardia to Report Fourth Quarter and Full Year 2019 Financial Results on Thursday, February 27, 2020

February 20, 2020 at 8:00 AM EST

BRISBANE, Calif., Feb. 20, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced that it will report fourth quarter and full year 2019 financial and operating results on Thursday, February 27, 2020. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 4:30 p.m. ET (1:30 p.m. PT). 

Conference Call and Webcast
Analysts and investors are invited to participate in the conference call by calling 844-494-0193 from the U.S. and Canada or 508-637-5584 internationally and using the conference ID 8698045.

The webcast may be accessed live on the Investor Relations section of the Company's website at http://investors.myokardia.com. A replay of the webcast will be available on the MyoKardia website for 90 days following the call.

About MyoKardia
MyoKardia is a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases. The company is pioneering a precision medicine approach to its discovery and development efforts by 1) understanding the biomechanical underpinnings of disease, 2) targeting the proteins that modulate a given condition, 3) identifying patient populations with shared disease characteristics and 4) applying learnings from research and clinical studies to inform and guide pipeline growth and advancement. MyoKardia’s initial focus is on small molecule therapeutics aimed at the muscle proteins of the heart that modulate cardiac muscle contraction to address diseases driven by excessive contraction, impaired relaxation, or insufficient contraction. Among its discoveries are three clinical-stage therapeutics: mavacamten (formerly MYK-461) in Phase 3 and Phase 2 clinical trials for hypertrophic cardiomyopathy (HCM); MYK-491 in Phase 2 for patients with stable heart failure; and MYK-224 in Phase 1 development for HCM.

MyoKardia’s mission is to change the world for people with serious cardiovascular disease through bold and innovative science.

Contacts

Michelle Corral
Corporate Communications & Investor Relations
MyoKardia, Inc.
650-351-4690
mcorral@myokardia.com

Hannah Deresiewicz (investors)
Stern Investor Relations, Inc.
212-362-1200
hannah.deresiewicz@sternir.com

MyoKardia_Logo_RGB.png

Source: MyoKardia, Inc.